Indications for: ENJAYMO
Treatment of hemolysis in adults with cold agglutinin disease (CAD).
See full labeling. Give by IV infusion over 1–2hrs based on body weight; infuse over 2hrs for patients with cardiopulmonary disease. Administer 6500mg (for patients weighing 39–<75kg) or 7500mg (for patients weighing ≥75kg) once weekly for the 1st 2 weeks, then every 2 weeks thereafter. Monitor for at least 2hrs after initial infusion and for 1hr after subsequent infusions for any infusion and/or hypersensitivity reactions.
Increased risk of serious infections (including encapsulated bacteria N. meningitides (any serogroup), S. pneumoniae, H. influenzae). Vaccinate or revaccinate against encapsulated bacteria at least 2 weeks prior to initiation according to current ACIP guidelines; if urgent treatment is indicated in an unvaccinated patient, give vaccine(s) as soon as possible. Active systemic infections: monitor closely for worsening infection. Consider interruption if undergoing treatment for serious infections. Chronic systemic infections (eg, HBV, HCV, or HIV): not studied. Discontinue and provide supportive measures if hypersensitivity reactions occur. Monitor for infusion-related reactions, recurrent hemolysis after treatment discontinuation. Potential risk for autoimmune diseases (eg, SLE); monitor. Pregnancy. Nursing mothers.
Rhinitis, headache, hypertension, acrocyanosis, Raynaud’s phenomenon, UTI, respiratory tract infection, bacterial infection, dizziness, fatigue, peripheral edema, arthralgia, cough, hypertension, nausea.
Half-life: 21 days.
Generic Drug Availability:
Single-dose vial (22mL)—1